Geschäftskunden Kundenprogramme
Vor Ort
Merkzettel Warenkorb
  • Produktbild: Phosphodiesterases as Drug Targets
  • Produktbild: Phosphodiesterases as Drug Targets
Band 204

Phosphodiesterases as Drug Targets

Aus der Reihe Handbook of Experimental Pharmacology

Fr. 360.00

inkl. gesetzl. MwSt., Versandkostenfrei

Beschreibung

Produktdetails

Einband

Taschenbuch

Erscheinungsdatum

26.11.2013

Herausgeber

Sharron H. Francis + weitere

Verlag

Springer Berlin

Seitenzahl

522

Maße (L/B/H)

23.5/15.5/2.9 cm

Gewicht

809 g

Auflage

2011

Sprache

Englisch

ISBN

978-3-642-26945-5

Beschreibung

Produktdetails

Einband

Taschenbuch

Erscheinungsdatum

26.11.2013

Herausgeber

Verlag

Springer Berlin

Seitenzahl

522

Maße (L/B/H)

23.5/15.5/2.9 cm

Gewicht

809 g

Auflage

2011

Sprache

Englisch

ISBN

978-3-642-26945-5

Herstelleradresse

Springer-Verlag KG
Sachsenplatz 4-6
1201 Wien
AT

Email: GPSR Kontakt

Noch keine Bewertungen vorhanden

Verfassen Sie die erste Bewertung zu diesem Artikel

Helfen Sie anderen Kundinnen und Kunden durch Ihre Meinung.

Kundinnen und Kunden meinen

Bewertungen (0)
  • Produktbild: Phosphodiesterases as Drug Targets
  • Produktbild: Phosphodiesterases as Drug Targets
  • Phosphodiesterase inhibitors: History of pharmacology; PDE inhibitors: factors that influence potency, selectivity and action; A fission yeast-based platform for phosphodiesterase inhibitor high throughput screening and analyses of phosphodiesterase activity; The pharmacokinetics of PDE inhibitors and the impact of this on their efficacy and the therapeutic window; Structural insight into the substrate specificity of phosphodiesterases;
    The GAF-tandem domain of phosphodiesterase 5 as a potential drug target; Small molecule allosteric modulators of phosphodiesterase 4; PDE 2 holoenzyme-insights about full length PDE and mechanism of activation by cGMP binding; Harnessing the clinical efficacy of phosphodiesterase 4 inhibitors in inflammatory lung diseases with dual-selective phosphodiesterase inhibitors and novel combination therapies; PDE inhibitors in the treatment of inflammatory diseases; Cyclic nucleotides and phosphodiesterases in monocyte differentiation; PDEs as targets for modulating T cell responses; Role of PDEs in adult-onset pulmonary arterial hypertension; Phosphodiesterases: emerging therapeutic targets for neonatal pulmonary hypertension; Phosphodiesterase inhibition in heart failure
    Evaluation of the Therapeutic Utility of Phosphodiesterase 5A Inhibition in the mdx Mouse
    Model of Duchenne Muscular Dystrophy; PDEs as targets for intermittent claudication;
    Treatment of erectile dysfunction and lower urinary tract symptoms by phosphodiesterase
    inhibitors; Regulation of endothelial barrier function by cyclic nucleotides: the role of phosphodiesterases; Potential use of PDE inhibitors in treatment of depression and improvement of cognition; PDEs as targets for the treatment of basal ganglia disorders
    Therapeutic potential of PDE inhibitors in parasitic diseases